Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialJuanita Lopez, Thomas Powles, Fadi Braiteh et al.|Nature Medicine|2025Cited by 104
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trialArlene O. Siefker‐Radtke, Wei Xue, Nobuaki Matsubara et al.|Annals of Oncology|2023Cited by 82
A phase 1/2 study of JK06, a 5T4 antibody drug conjugate, in patients with unresectable locally advanced or metastatic cancer.Nuria Kotecki, Naimish Pandya, Valentina Boni et al.|Journal of Clinical Oncology|2025Cited by 0